Seletalisib

DB12706InvestigationalSmall molecule

Seletalisib has been used in trials studying the treatment and basic science of Primary Sjogren's Syndrome.

Mechanism: Pharmacologically active on Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
Curator reviewed
Formula / weight: C₂₃H₁₄ClF₃N₆O · 482.85 g/mol (avg)
Code names: UCB-5857

Resolves to

Compound

Structure

InChIKeyLNLJHGXOFYUARS-OAQYLSRUSA-NSMILES[O-][N+]1=CC(=CC=C1)C1=NC2=C(Cl)C=CC=C2C=C1[C@@H](NC1=NC=NC2=CC=CN=C12)C(F)(F)F

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Seletalisib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.